Evidence map›Paper›PMID 41279198›Full record

ArticlebioRxiv : the preprint server for biology2025

Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockade.

Kathryne E Marks, Anina Sun, Ifeoluwakiisi Adejoorin, Lourdes Perez Chada, Anna Perillo, Leanne Barrett, Michael Garshick, James Krueger, Joseph F Merola, Marcelo DiCarli and 2 more

Registry-linked trialAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04271540 (Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe Psoriasis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04271540 phase4completednot on this map

Effects of Tildrakizumab on Coronary Microvascular Function in Moderate-Severe Psoriasis

TypeinterventionalSponsorMarcelo F. Di Carli, MD, FACCRan2020 to 2024Enrolled36ConditionsPsoriasis, Cardiovascular DiseaseArmsTildrakizumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kathryne E MarksDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Anina SunDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ifeoluwakiisi AdejoorinDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Lourdes Perez ChadaDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Anna PerilloDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Leanne BarrettDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Michael GarshickLeon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, New York.
James KruegerLaboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
Joseph F MerolaDepartment of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, TX, USA.
Marcelo DiCarliDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Deepak A RaoDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Brittany N WeberDivision of Rheumatology, Inflammation, Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Advanced CV imaging and immunophenotyping to study coronary vascular health in psoriasisK23HL159276 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI WEBER, BRITTANY NICOLE · 2021 to 2025
$962k
NHLBI NIH HHS K23 HL159276NIAMS NIH HHS P30 AR070253
6 · The paper itself

Abstract

The use of IL-23 inhibitors (IL-23i) for psoriatic diseases has resulted in significant improvement in disease symptoms for many patients. The extent of disease improvement following IL-23 blockade varies across patients with psoriasis; however, the immunologic factors associated with a good or poor response to IL-23 blockade remain unclear. Here, we utilized peripheral blood mononuclear cells (pBMCs) collected through the MINIMA clinical trial (NCT04271540) and applied single-cell RNA sequencing to profile circulating immune populations from 27 patients with psoriasis or psoriatic arthritis, aiming to identify cellular features associated with a response to IL-23 blockade. We identified populations of CD4

Identifiers

PMID41279198
PMCPMC12637652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.